- Home
- DTIL vs ARMP Comparison
DTIL vs ARMP Comparison
Compare DTIL & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- ARMP
- Stock Information
- Founded
- DTIL 2006
- ARMP N/A
- Country
- DTIL United States
- ARMP United States
- Employees
- DTIL N/A
- ARMP N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTIL Health Care
- ARMP Health Care
- Exchange
- DTIL Nasdaq
- ARMP Nasdaq
- Market Cap
- DTIL 51.6M
- ARMP 52.1M
- IPO Year
- DTIL 2019
- ARMP N/A
- Fundamental
- Price
- DTIL $5.01
- ARMP $1.96
- Analyst Decision
- DTIL Strong Buy
- ARMP Strong Buy
- Analyst Count
- DTIL 2
- ARMP 1
- Target Price
- DTIL $47.00
- ARMP $9.00
- AVG Volume (30 Days)
- DTIL 74.8K
- ARMP 624.1K
- Earning Date
- DTIL 05-15-2025
- ARMP 05-14-2025
- Dividend Yield
- DTIL N/A
- ARMP N/A
- EPS Growth
- DTIL N/A
- ARMP N/A
- EPS
- DTIL N/A
- ARMP N/A
- Revenue
- DTIL $51,141,000.00
- ARMP $4,699,000.00
- Revenue This Year
- DTIL N/A
- ARMP $8.43
- Revenue Next Year
- DTIL $30.20
- ARMP N/A
- P/E Ratio
- DTIL N/A
- ARMP N/A
- Revenue Growth
- DTIL N/A
- ARMP 14.24
- 52 Week Low
- DTIL $3.61
- ARMP $0.90
- 52 Week High
- DTIL $13.32
- ARMP $3.42
- Technical
- Relative Strength Index (RSI)
- DTIL 49.26
- ARMP 58.73
- Support Level
- DTIL $4.72
- ARMP $1.90
- Resistance Level
- DTIL $5.10
- ARMP $2.20
- Average True Range (ATR)
- DTIL 0.26
- ARMP 0.33
- MACD
- DTIL 0.01
- ARMP 0.03
- Stochastic Oscillator
- DTIL 50.16
- ARMP 55.46
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.